Advertisement

The Control of Cytomegalovirus Infection: Chemotherapy

  • Jonathan S. Serody
  • Charles M. van der Horst
Part of the Frontiers of Virology book series (FRVIROLOGY, volume 2)

Abstract

The pharmacokinetic profile, efficacy and toxicity of the two principal chemotherapeutic agents, ganciclovir and foscarnet, utilized in the treatment of cytomegalovirus infection in the immunocompromised host are reviewed. In addition, the efficacy, cost and safety of the various prophylactic regimens for prevention of cytomegalovirus disease is examined. Recommendations for treatment and prophylaxis in HIV infected and transplant recipients are given.

Keywords

Transplant Recipient Renal Transplant Recipient Cytomegalovirus Infection Cytomegalovirus Retinitis Oral Ganciclovir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alfred CA (1984) Chronic intrauterine and perinatal infections. In: Galasso GJ, Merigan TC, Buchanan RA (eds) Antiviral agents and viral diseases of man, 2nd edn. Raven, New York, pp 433–486Google Scholar
  2. 2.
    Aweeka F, Gambertoglio JG, Mills J, Jacobson MA (1989) Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. Antimicrob Agents Chemother 33: 742–745PubMedGoogle Scholar
  3. 3.
    Bailey T, Ettinger N, Storch G, Cooper J et al. (1991) Failure of prophylactic ganciclovir to prevent cytomegalovirus pneumonitis in lung transplant recipients. Abstract 778 of the 1991 Interscience Conference on Antimicrobial Agents and Chemotherapy, ChicagoGoogle Scholar
  4. 4.
    Balfour HH Jr, Bean B, Edelman CK et al. (1982) Acyclovir in immunocompromised patients with cytomegalovirus disease: a controlled trial at one institution. Am J Med 73: 241–248PubMedGoogle Scholar
  5. 5.
    Balfour HH Jr, Bean B, Laskin OL (1983) Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 308: 1448–1453PubMedGoogle Scholar
  6. 6.
    Balfour HH Jr, Chace BA, Stapleton JT et al. (1989) A randomized placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 320: 1381–1387PubMedGoogle Scholar
  7. 7.
    Barkholt LM, Ericzon BG, Ehrnst A et al. (1990) Cytomegalovirus infections in liver transplant patients: incidence and outcome. Transplant Proc 22: 235–237PubMedGoogle Scholar
  8. 8.
    Bean B, Braun C, Balfour HH Jr (1982) Acyclovir therapy for acute herpes zoster. Lancet 2: 118–121PubMedGoogle Scholar
  9. 9.
    Betts RF (1984) The relationship of epidemiology and treatment factors to infection and allograft survival in renal transplantation. In: Plotkin SA, Michelson S, Patano J, et al. (eds) CMV: pathogenesis and prevention of human infection, birth defects: original article series, vol 20. Liss, New York, pp 87–99Google Scholar
  10. 10.
    Biron KK, Stanat SC, Sorrell JB et al. (1985) Metabolic activation of the nucleoside analog 9-((2-hydroxy-1-(hydroxmethyl)ethoxy)methyl)guanine in human diploid fibroblasts infected with human CMV. Proc Natl Acad Sci USA 82: 2473–2477PubMedGoogle Scholar
  11. 11.
    Blacklock HA, Griffiths P, Stirk P et al. (1985) Specific hyperimmune globulin for cytomegalovirus pneumonitis. Lancet 2: 152–153PubMedGoogle Scholar
  12. 12.
    Blum RM, Liao SHT, de Miranda P (1982) Overview of acyclovir pharmacokinetic disposition in adults and children. Am J Med 73 (supp): 186–192PubMedGoogle Scholar
  13. 13.
    Bowden RA, Sayers M, Flournoy N, Newton B et al. (1986) Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314: 1006–1010PubMedGoogle Scholar
  14. 14.
    Bowden RA, Fisher LD, Rogers K, Cays M, Meyers JD (1991) Cytomegalovirusspecific intravenous immunoglobulin for prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 164: 483–487PubMedGoogle Scholar
  15. 15.
    Bowden RA, Reusser P, Cays M, Meyers JD (1991) The use of foscarnet for treatment of cytomegalovirus-associated marrow suppression after marrow transplant. Abstract 777 of the 1991 Interscience Conference on Antimicrobial Agents and Chemotherapy, ChicagoGoogle Scholar
  16. 16.
    Bower M, Barton SE, Nelson MR et al. (1990) The significance of the detection of cytomegalovirus in the bronchoalveolar lavage fluid in AIDS patients with pneumonia. AIDS 4: 317–320PubMedGoogle Scholar
  17. 17.
    Bratanow NC, Ash RC, Casper J et al. (1987) Successful treatment of serious cytomegalovirus (CMV) disease with 9,(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir, DHPG) and intravenous immunoglobulin (IVIG) in bone marrow transplant (BMT) patients (abstract 254). Exp Hematol 15: 541Google Scholar
  18. 18.
    Broughton WL, Cupples HP, Parver LM (1978) Bilateral retinal detachment following cytomegalovirus retinitis. Arch Ophthalmol 96: 618–619PubMedGoogle Scholar
  19. 19.
    Causey D (1991) Concomitant ganciclovir and zidovudine treatment for cytomegalovirus retinitis in patients with HIV infection: an approach to treatment. J Acquir Immun Defic Syndr 4 [Suppl 1]: S16 - S21Google Scholar
  20. 20.
    Chou S, Dylewski JS, Gaynon MW, Egbert PR, Merigan TC (1984) Alpha-interferon administration in cytomegalovirus retinitis. Antimicrob Agents Chemother 25: 25–28PubMedGoogle Scholar
  21. 21.
    Chrisp P, Clissold SP (1991) Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41: 104–129PubMedGoogle Scholar
  22. 22.
    Cofer JB, Morris CA, Sutker WL, Husberg BS et al. (1991) A randomized double-blind study of the effect of prophylactic immune globulin on the incidence and severity of CMV infection in the liver transplant recipient. Transplant Proc 23: 1525–1527PubMedGoogle Scholar
  23. 23.
    Cole NL, Balfour HH Jr (1987) In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 6: 255–261PubMedGoogle Scholar
  24. 24.
    De Gans J, Portegies P, Tiessens G et al. (1990) Therapy for cytomegalovirus polyradiculomyelitis in patients with AIDS: treatment with ganciclovir. AIDS 4: 421–425PubMedGoogle Scholar
  25. 25.
    Delaroque E, Masio C, Salmon-Ceron D, Girard PM et al. (1991) Sclerosing cholangitis in 14 AIDS patients: diagnosis and outcome. Abstract M.B. 2287, V II International Conference on AIDS, FlorenceGoogle Scholar
  26. 26.
    De Miranda P, Good SS, Laskin OL et al. (1981) Disposition of intravenous radioactive acyclovir. Clin Pharmacol Ther 30: 662PubMedGoogle Scholar
  27. 27.
    Deray G, Katlama C, Dohin E (1990) Prevention of foscarnet nephrotoxicity (letter). Ann Intern Med 113: 332PubMedGoogle Scholar
  28. 28.
    Deray G, Martinez F, Beufils H et al. (1990) Foscarnet nephrotoxicity, mechanism, incidence and prevention. Am J Nephrol 9: 316–321Google Scholar
  29. 29.
    Dieterich DT, Rahmin M (1991) Cytomegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immun Defic Syndr 4 [Suppl 1]: S29 - S34Google Scholar
  30. 30.
    Dieterich DT, Chachoua A, Lafleur F et al. (1988) Ganciclovir treatment of gastrointestinal infections caused by cytomegalovirus in patients with AIDS. Rev Inf Dis 10 [Suppl 3]: S532 - S537Google Scholar
  31. 31.
    Dieterich D, Kotler D, Busch D, Crumpacker C et al. (1990) Randomized, placebo-controlled study of ganciclovir treatment of cytomegalovirus colitis in AIDS patients. Abstract F.B.94, VI International Conference on AIDS, San Francisco, June 20–24Google Scholar
  32. 32.
    Dieterich D, Dicker M, Tepper R (1991) Foscarnet treatment of cytomegalovirus gastrointestinal infections in AIDS patients who have failed ganciclovir. Abstract W.B.2293, V II International Conference on AIDS, FlorenceGoogle Scholar
  33. 33.
    Dohin E, Katlama C, Hoang P et al. (1990) Intermittent and ambulatory treatment of CMV retinitis with foscarnet in AIDS. Abstract Th.B.434, VI International Conference on AIDS, San Francisco, June 20–24Google Scholar
  34. 34.
    Dohin E, Katlama C, Brancon C, Caumes E et al. (1991) Foscarnet in maintenance therapy of cytomegalovirus retinitis in AIDS. Abstract W.B.2285, V II International Conference on AIDS, FlorenceGoogle Scholar
  35. 35.
    Dorsky DI, Crumpacker CS (1987) Drugs five years later: acyclovir. Ann Intern Med 107: 859–874PubMedGoogle Scholar
  36. 36.
    Drew WL, Lalezari J, Busch D, Follansbee S et al. (1991) In vivo antiviral efficacy of oral ganciclovir. Abstract W.B.2309, V II International Conference on AIDS, FlorenceGoogle Scholar
  37. 37.
    Drew WL, Miner R, Busch D, Follansbee S et al. (1991) Prevalence of resistance in patients receiving ganciclovir for serious CMV infection. J Infect Dis 716–719Google Scholar
  38. 38.
    Dunn DL, Mayoral JL, Gillingham KJ et al. (1991) Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 51: 98–106PubMedGoogle Scholar
  39. 39.
    Emanuel D, Cunningham I, Jules-Elysee K et al. (1988) Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 109: 777–782PubMedGoogle Scholar
  40. 40.
    Eriksson B, Oberg B, Wahren B (1982) Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta 696: 115–123PubMedGoogle Scholar
  41. 41.
    Estes JE, Huang ES (1977) Stimulation of cellular thymidine kinases by human cytomegalovirus. J Virol 24: 13–21PubMedGoogle Scholar
  42. 42.
    Felsenstein D, D’Amico DJ, Hirsch MS et al. (1985) Treatment of cytomegalovirus retinitis with 9(2-hydroxy-1-(hydroxymethyl)ethoxymethyl)guanine. Ann Intern Med 103: 377–380PubMedGoogle Scholar
  43. 43.
    Fletcher C, Sawchuk R, Balfour HH Jr et al. (1986) Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 40: 281–286PubMedGoogle Scholar
  44. 44.
    Follansbee S, Busch D, Connor J, Jung D et al. (1990) Phase I study of the safety and pharmacokinetics of oral ganciclovir. Abstract F.B.91, VI International Conference on AIDS, San Francisco, June 20–24Google Scholar
  45. 45.
    Foscarnet (1992) Med Lett Drugs Ther 34 (861): 3–4Google Scholar
  46. 46.
    Freeman WR, Henderly DE, Wan WL et al. (1987) Prevalence, pathophysiology, and treatment of rhegmatogenous retinal detachment in treated cytomegalovirus retinitis. Am J Ophthalmol 103: 527–536PubMedGoogle Scholar
  47. 47.
    Furman PA, de Miranda P, St. Clair MH et al. (1981) Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother 20: 518–524PubMedGoogle Scholar
  48. 48.
    Furman PA, St. Clair MH, Spector T (1984) Acyclovir triphosphate is a suicidal inactivator of the herpes simplex virus DNA polymerase. J Biol Chem 259: 9575–9579PubMedGoogle Scholar
  49. 49.
    Gentilini M, Dohin E, Cochereau I, Brancon C et al. (1991) Foscarnet in acute therapy of CMV retinitis: experience with a twice daily intermittent regimen. Abstract W.B.2257, V II International Conference on AIDS, FlorenceGoogle Scholar
  50. 50.
    Gilquin J, Weiss L, Kazatchkine MD (1990) Genital and oral erosions induced by foscarnet. Lancet 335: 287PubMedGoogle Scholar
  51. 51.
    Gross JG, Bozzette SA, Matthews WC et al. (1990) Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology 97: 681–686PubMedGoogle Scholar
  52. 52.
    Hagenbeck A, Brummelhuis HGJ, Lowenberg B et al. (1987) Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients. J Infect Dis 155: 897–902Google Scholar
  53. 53.
    Hardy D, Spector S, Polsky B, Heath-Chiozzi M et al. (1990) Safety and efficacy of combined ganciclovir and granulocyte-macrophage stimulating factor vs ganciclovir alone for cytomegalovirus retinitis in AIDS (ACTG 073): a preliminary report. Abstract F.B.92, VI International Conference on AIDS, San Francisco, June 20–24Google Scholar
  54. 54.
    Helgstrand E, Flodh H, Oberg B et al. (1980) Trisodium phosphonoformate: antiviral activities, safety evaluation and preliminary clinical results. Ber Dtsch Chem Ges 78:1023–1038Google Scholar
  55. 55.
    Henderly DE, Freeman WR, Causey DM, Rao NA (1987) Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 94: 425–434PubMedGoogle Scholar
  56. 56.
    Henry K, Cantrill H, Fletcher C et al. (1987) Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol 103: 17–23PubMedGoogle Scholar
  57. 57.
    Ho M (1982) Treatment and prevention of CMV infection. In: Greenough WB III, Merigan TC (eds) Cytomegalovirus, biology and infection: current topics in infectious disease. Plenum, New York, pp 205–213Google Scholar
  58. 58.
    Hochster H, Dieterich D, Bozzette S, Reichman RC, et al. (1990) Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med 113: 111–117PubMedGoogle Scholar
  59. 59.
    Holland GN, Pepose JS, Pettit TH et al. (1983) Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 90: 859–873PubMedGoogle Scholar
  60. 60.
    Holland GN, Sidikaro Y, Kreiger AE et al. (1987) Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 94: 815–823PubMedGoogle Scholar
  61. 61.
    Holland GN, Sison RF, Jatulis DE et al. (1990) Survival of patients with the acquired immune deficiency syndrome after development of cytomegalovirus retinopathy. Ophthalmology 97: 204–211PubMedGoogle Scholar
  62. 62.
    Hooton TM, Dejarnette L, Tartaglione T, Paar D, et al. (1991) Serial phase II dose-escalation studies of the oral pyrimidine nucleoside analog FIAC and its metabolite FIAU in HIV-infected patients (ACTG 122). Abstract 1218. Program and Abstracts, 31st Interscience Conference on Antimicrobial Agents and ChemotherapyGoogle Scholar
  63. 63.
    Huang ES (1975) Human cytomegalovirus: specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid. J Virol 16: 1560–1565PubMedGoogle Scholar
  64. 64.
    Huang ES, Benson JD, Huong SM, Wilson B et al. (1992) Irreversible inhibition of human cytomegalovirus replication by topoisomerase II inhibitor, etoposide: a new strategy for the treatment of human cytomegalovirus infection. Antiviral Res 17: 17–32PubMedGoogle Scholar
  65. 65.
    Investigational brochure, intravenous ganciclovir, 9th edn (1991) Syntex Research, Palo Alto, CaliforniaGoogle Scholar
  66. 66.
    Jabs DA, Enger C, Bartlett JG (1989) Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 107: 75–80PubMedGoogle Scholar
  67. 67.
    Jabs DA, Newman C, De Bustros S, Polk BF et al. (1987) Treatment of cytomegalovirus retinitis with ganciclovir. Ophthalmology 94: 824–830PubMedGoogle Scholar
  68. 68.
    Jacobson MA, De Miranda P, Cederberg DM et al. (1987) Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother 31: 1251–1254PubMedGoogle Scholar
  69. 69.
    Jacobson MA, Crowe S, Levy J et al. (1988) Effect of foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS. J Infect Dis 158: 862–865PubMedGoogle Scholar
  70. 70.
    Jacobson MA, O’Donnell JJ, Brodie HR (1988) Randomized prospective trial of ganciclovir maintenance therapy for cytomegalovirus retinitis. J Med Virol 25: 339–349PubMedGoogle Scholar
  71. 71.
    Jacobson MA, O’Donnell JJ, Mills J (1989) Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Antimicrob Agents Chemother 33: 736–741PubMedGoogle Scholar
  72. 72.
    Jacobson MA, Causey D, Polsky B, Hardy D et al. (1990) Dose-ranging study of daily intravenous maintenance foscarnet therapy for cytomegalovirus retinitis in AIDS patients (ACTG 015/915). Abstract F.B.96, VI International Conference on AIDS, San Francisco, June 20–24Google Scholar
  73. 73.
    Jacobson MA, Gambertoglio JG, Aweeka FT et al. (1991) Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab 72: 1130–1135PubMedGoogle Scholar
  74. 74.
    Jacobson MA, Wulfsohn M, Feinberg J, Davis R et al. (1991) Phase 2 dose-ranging study of foscarnet salvage therapy for CMV retinitis in patients intolerant of or resistant to ganciclovir therapy (ACTG 093). Abstract 296, 1991 Interscience Conference on Antimicrobial Agents and Chemotherapy, ChicagoGoogle Scholar
  75. 75.
    Kaplan CS, Petersen EA, Icenogle TB et al. (1989) Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients. Arch Intern Med 149: 2095–2100PubMedGoogle Scholar
  76. 76.
    Kasiske BL, Heim-Duthoy KL, Tortorice KL, Ney AL et al. (1989) Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. Arch Intern Med 149: 2733PubMedGoogle Scholar
  77. 77.
    Keay S, Petersen E, Icenogle TB et al. (1988) Ganciclovir treatment of serious cytomegalovirus infection in heart and heart-lung transplant recipients. Rev Inf Dis 10 [Suppl 3]: 5563 - S572Google Scholar
  78. 78.
    King SM, Petric M, Superina R et al. (1990) Cytomegalovirus infections in pediatric liver transplantation. Am J Dis Child 144: 1307–1310PubMedGoogle Scholar
  79. 79.
    Klintmalm G, Lonnqvist B, Oberg B et al. (1985) Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. Scand J Infect Dis 17: 157–163PubMedGoogle Scholar
  80. 80.
    Kovacs A, Schmidt GM, Zaia JA et al. (1988) Ganciclovir (GCV) plus intravenous immunoglobulin (IVIG) treatment of human cytomegalovirus interstitial pneumonia (HCMV-IP) in recipients of allogeneic bone marrow transplantation (BMT). Abstract 738, Program and Abstracts, 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DCGoogle Scholar
  81. 81.
    Laske A, Gallino A, Mohacsi P, Bauer EP et al. (1991) Prophylactic treatment with ganciclovir for cytomegalovirus infection in heart transplantation. Transplant Proc 23: 1170–1173PubMedGoogle Scholar
  82. 82.
    Laskin OL, Longstreth C, Whelton A et al. (1982) Effect of renal failure on the pharmacokinetics of acyclovir. Am J Med 73 [Suppl]: 197–201PubMedGoogle Scholar
  83. 83.
    Laskin OL, Cederberg DM, Mills J et al. (1987) Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus. Am J Med 83: 201–207PubMedGoogle Scholar
  84. 84.
    Linden P, Dummer S, Kusne S, Ho M et al. (1991) Cytomegalovirus hepatitis following orthotopic liver transplantation: effect of 9-(1,3 dihydroxy-2-propoxymethyl) guanine on CMV-related morbidity. Abstract 1241, 1991 Interscience Conference on Antimicrobial Agents and Chemotherapy, ChicagoGoogle Scholar
  85. 85.
    Manischewitz JF, Quinnan GV, Lane HC, Wittek AE (1990) Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 34: 373–375PubMedGoogle Scholar
  86. 86.
    Mayoral JL, Loeffer CM, Fasola CG et al. (1991) Diagnosis and treatment of cytomegalovirus disease in transplant patients based on gastrointestinal tract manifestations. Arch Surg 126: 202–206PubMedGoogle Scholar
  87. 87.
    McGuirt PV, Furman PA (1982) Acyclovir inhibition of viral DNA chain elongation in herpes simplex virus-infected cells. Am J Med 73 [Suppl]: 67–71PubMedGoogle Scholar
  88. 88.
    McKindrick MW, McGill JI, White JE et al. (1986) Oral acyclovir in acute herpes zoster. Br Med J 293: 1529–1532Google Scholar
  89. 89.
    Meredith TA, Aaberg TM, Reeser FH (1979) Rhegmatogenous retinal detachment complicating cytomegalovirus retinitis. Am J Ophthalmol 87: 793–796PubMedGoogle Scholar
  90. 90.
    Meyers JD, McGuffin RW, Neiman PE, Singer JW et al. (1980) Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J Infect Dis 141: 555–562PubMedGoogle Scholar
  91. 91.
    Meyers JD, Lescczynski J, Thomas ED et al. (1983) Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 98: 442–446PubMedGoogle Scholar
  92. 92.
    Meyers JD, Flournoy N, Thomas ED (1986) Risk factors for cytomegalovirus infection after bone marrow transplantation. J Infect Dis 153: 478–488PubMedGoogle Scholar
  93. 93.
    Meyers JD, Reed EC, Shepp DH et al. (1988) Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318: 70–75PubMedGoogle Scholar
  94. 94.
    Millar AB, Patou G, Semple SJ et al. (1990) Cytomegalovirus in the lungs of patients with AIDS. Am Rev Respir Dis 141: 1474–1477PubMedGoogle Scholar
  95. 95.
    Mintz L, Drew WL, Miner L et al. (1983) Cytomegalovirus infections in homosexual men: an epidemiological study. Ann Intern Med 99: 326–329PubMedGoogle Scholar
  96. 96.
    Nelson M, Connolly G, Hawkins D, Gazzard B (1991) Foscarnet in the treatment of cytomegalovirus infection of the oesophagus and colon. Abstract W.B.2262, V II International Conference on AIDS, FlorenceGoogle Scholar
  97. 97.
    Nerurkar LS, Biggar RJ, Goedert JJ et al. (1987) Antiviral antibodies in the sera of homosexual men: correlation with their lifestyle and drug usage. J Med Virol 21: 123–135PubMedGoogle Scholar
  98. 98.
    Nicholson ML, Veitch PS, Donnelly PK, Flower AJE, Bell PRF (1990) Treatment of renal transplant-associated cytomegalovirus infection with ganciclovir. Transplant Proc 22: 1811–1812PubMedGoogle Scholar
  99. 99.
    Orellana J, Teich SA, Friedman AH, Lerebours F et al. (1987) Combined short-and long-term therapy for the treatment of cytomegalovirus retinitis using ganciclovir (BW B759U). Ophthalmology 94: 831–838PubMedGoogle Scholar
  100. 100.
    Package insert for Foscarnet, Astra Pharmaceutical Products, Inc, Westborough, Mass.Google Scholar
  101. 101.
    Palestine AG, Stevens G, Lane HC et al. (1986) Treatment of cytomegalovirus retinitis with dihydroxy propoxymethylguanine. Am J Ophthalmol 101: 95–101PubMedGoogle Scholar
  102. 102.
    Plotkin SA, Friedman HM, Fleisher GR et al. (1981) Prevention and treatment of cytomegalovirus infection. In: Nahmias A, Dowdle W, Schinazi R (eds) The human herpesviruses: an interdisciplinary perspective. Elsevier, New York, pp 403–413Google Scholar
  103. 103.
    Polsky B, Wolitz R, Chuang EL, Cantrill H et al. (1991) Intravitreal ganciclovir salvage therapy for CMV retinitis (ACTG 085): a preliminary report. Abstract 295, 31st Inter-science Conference on Antimicrobial Agents and Chemotherapy, ChicagoGoogle Scholar
  104. 104.
    Potter JL, Krill CE (1986) Acyclovir crystalluria. Pediatr Infect Dis 5: 710–712PubMedGoogle Scholar
  105. 105.
    Prostegard C, Sjovall J, Arvidsson A et al. (1991) Pharmacokinetics of foscarnet — a review. Abstract W.B.2288, V II International Conference on AIDS, FlorenceGoogle Scholar
  106. 106.
    Reed EC, Dandliker PS, Meyers JD (1986) Treatment of cytomegalovirus pneumonia with 9-(2-hydroxy-1-(hydroxymethyl)-ethoxymethyl)guanine and high-dose corticosteroids. Ann Intern Med 105: 214–215PubMedGoogle Scholar
  107. 107.
    Reed EC, Bowden RA, Dandliker PS et al. (1987) Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis 156: 641–645PubMedGoogle Scholar
  108. 108.
    Reed EC, Bowden RA, Dandliker PS et al. (1988) Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 109: 783–788PubMedGoogle Scholar
  109. 109.
    Reed EC, Wolford JL, Kopecky KJ et al. (1990) Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. Ann Intern Med 112: 505–510PubMedGoogle Scholar
  110. 110.
    Rondeau E, Farquet C, Ruedin P et al. (1990) Efficacy of early treatment of cytomegalovirus infection by ganciclovir in renal transplant recipients. Transplant Proc 22: 1813–1814PubMedGoogle Scholar
  111. 111.
    Rosecan LR, Stahl-Bayliss CM, Kalman CM et al. (1986) Antiviral therapy for cytomegalovirus retinitis in AIDS with dihydroxy propoxymethylguanine. Am J Opthalmol 101: 405–418Google Scholar
  112. 112.
    Sandstrom EG, Byington RE, Hirsch MS et al. (1985) Inhibition of human T cell lymphotropic virus type III in vitro by phosphonoformate. Lancet 2: 1480–1482Google Scholar
  113. 113.
    Sawyer MH, Webb DE, Balow JE et al. (1988) Acyclovir-induced renal failure: clinical course and histology. Am J Med 84: 1067–1071PubMedGoogle Scholar
  114. 114.
    Schafers HJ, Wahlers T, Haverich A et al. (1988) Hyperimmuneglobulin for cytomegalovirus prophylaxis following heart transplantation. J Hosp Infect 2 [Suppl D]: 61–65Google Scholar
  115. 115.
    Schmidt GM, Horak DA, Niland JC (1991) A randomized controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 324: 1005–1011PubMedGoogle Scholar
  116. 116.
    Shepp DH, Dandliker PS, de Miranda P et al. (1985) Activity of 9-(2-hydroxy-1-(hydroxymethyl)ethoxymethyl)guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 103: 368–373PubMedGoogle Scholar
  117. 117.
    Sjovall J, Karlsson A, Ogenstad S et al. (1988) Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus. Clin Pharmacol Ther 44: 65–73PubMedGoogle Scholar
  118. 118.
    Snydman DR, McIver J, Grady GF et al. (1984) A pilot trial of a novel cytomegalovirus immune globulin in renal transplant recipients. Transplantation 38: 553–557PubMedGoogle Scholar
  119. 119.
    Snydman DR, Werner BG, Heinze-Lacey B et al. (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317: 1049–1054PubMedGoogle Scholar
  120. 120.
    Syndman DR, Werner BG, Heinze-Lacey B et al. (1988) A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial. Transplant Proc 20 [Supp] 81: 24–30Google Scholar
  121. 121.
    Snydman DR, Werner BG, Rubin RH (1991) The use of cytomegalovirus immune globulin for prevention of CMV disease in patients undergoing liver transplantation. Abstract 1242, 1991 Interscience Conference on Antimicrobial Agents and Chemotherapy, ChicagoGoogle Scholar
  122. 122.
    Sommadossi JP, Bevan R, Ling T et al. (1988) Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function. Rev Infect Dis 10 (Suppl 3): 5507–5514Google Scholar
  123. 123.
    Spector SA, Barker C, Buhles W, Feinberg J et al. (1991) A randomized, controlled study of immediate vs deferred ganciclovir therapy in AIDS patients with cytomegalovirus peripheral retinitis. Abstract M.B.86, V II International Conference on AIDS, FlorenceGoogle Scholar
  124. 124.
    Stanat SC, Reardon JE, Erice A, Jordan MC et al. (1991) Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 35: 2191–2197PubMedGoogle Scholar
  125. 125.
    Stratta RJ, Shaefer MS, Cushing KA, Markin RS et al. (1991) Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation 51: 90–97PubMedGoogle Scholar
  126. 126.
    Studies of Ocular Complications of AIDS Research Group et al. (1992) Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. New Engl J Med 326: 213–220Google Scholar
  127. 127.
    Sullender WM, Arvin AM, Diaz PS et al. (1987) Pharmacokinetics of acyclovir suspension in infants and children. Antimicrob Agents Chemother 31: 1722–1726PubMedGoogle Scholar
  128. 128.
    Van Der Pijl JW, Frissen PHJ, Reiss P et al. (1990) Foscarnet and penile ulceration. Lancet 335: 286Google Scholar
  129. 129.
    Van Dyke RB, Connor JD, Wyborny C et al. (1982) Pharmacokinetics of orally administered acyclovir in patients with herpes progenitalis. Am J Med 73 [Suppl]: 172–175PubMedGoogle Scholar
  130. 130.
    Vasudevan VP, Mascarenhas DAN, Lomvaridias S et al. (1990) Cytomegalovirus necrotizing bronchiolitis with HIV infection. Chest 97: 483–484PubMedGoogle Scholar
  131. 131.
    Wade JC, Hintz M, McGuffin RW et al. (1982) Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med 73 [Suppl la]: 249–256PubMedGoogle Scholar
  132. 132.
    Walmsley SL, Chew E, Reed SE et al. (1988) Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (foscarnet). J Infect Dis 157: 569–572PubMedGoogle Scholar
  133. 133.
    Winston DJ, Pollard RB, Ho WG et al. (1982) Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 97: 11–18PubMedGoogle Scholar
  134. 134.
    Winston DJ, Ho WG, Lin C-H, Bartoni K et al. (1987) Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106: 12–18PubMedGoogle Scholar
  135. 135.
    Wool M, Hardy D, Holland G, Chafey Set al. (1991) Phase III recombinant GM-CSF and ganciclovir in neutropenic AIDS patients with CMV retinitis. Abstract W.B.2273, V II International Conference on AIDS, FlorenceGoogle Scholar
  136. 136.
    Youle MS, Clarbour J, Gazzard B et al. (1988) Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine (letter). Lancet 2: 1455–1456Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • Jonathan S. Serody
    • 1
  • Charles M. van der Horst
    • 1
  1. 1.Division of Infectious DiseaseUniversity of North CarolinaChapel HillUSA

Personalised recommendations